Precigen, Inc. (NASDAQ:PGEN – Get Free Report) COO Rutul Shah sold 34,658 shares of the company’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $7.50, for a total transaction of $259,935.00. Following the completion of the transaction, the chief operating officer directly owned 465,012 shares of the company’s stock, valued at $3,487,590. This represents a 6.94% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Precigen Price Performance
NASDAQ:PGEN opened at $7.42 on Thursday. The company has a quick ratio of 3.89, a current ratio of 4.58 and a debt-to-equity ratio of 2.15. The business’s 50-day simple moving average is $5.96 and its two-hundred day simple moving average is $4.71. The stock has a market cap of $2.65 billion, a PE ratio of -7.13 and a beta of 1.02. Precigen, Inc. has a 52 week low of $2.99 and a 52 week high of $7.72.
Precigen (NASDAQ:PGEN – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.06. Precigen had a positive return on equity of 423.75% and a negative net margin of 183.98%.The firm had revenue of $54.98 million during the quarter, compared to analyst estimates of $27.98 million. The business’s revenue for the quarter was up 6322.7% on a year-over-year basis. As a group, analysts forecast that Precigen, Inc. will post 0.25 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Report on Precigen
More Precigen News
Here are the key news stories impacting Precigen this week:
- Positive Sentiment: Strong PAPZIMEOS sales and profitability: Precigen reported that PAPZIMEOS generated $53.1 million in second-quarter net product revenue, more than double the prior quarter. The product’s performance helped the company achieve quarterly profitability and represents a significant commercial inflection point. Precigen second-quarter update
- Positive Sentiment: Pipeline progress supports the growth outlook: PRGN-2009 is advancing in HPV-driven cancers, and management highlighted broader potential for the AdenoVerse platform. The combination of growing product revenue and additional pipeline opportunities is strengthening the investment case. AdenoVerse platform and PRGN-2009 update
- Positive Sentiment: Favorable external sentiment: Zacks included PGEN among five biotech stocks worth considering, citing industry momentum, pipeline progress and the company’s portfolio. Recent coverage also notes a consensus “Moderate Buy” rating and a $14.50 price target, although analyst opinions remain mixed. Zacks biotech stock selection
- Positive Sentiment: Director buying: Director Nancy Agee purchased 3,411 shares at $7.23, increasing her ownership by 1.12%. The insider purchase may signal confidence in Precigen’s outlook.
- Neutral Sentiment: COO sales were administrative: COO Rutul Shah sold a combined 50,000 shares at approximately $7.50 under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards. The transactions reduce his holdings but are less bearish than discretionary selling.
- Neutral Sentiment: Momentum and risk: PGEN reached a new one-year high, reinforcing bullish momentum, but elevated valuation expectations and the company’s historically negative net margin leave the stock sensitive to future sales and clinical updates. Precigen reaches a new one-year high
Institutional Trading of Precigen
A number of large investors have recently added to or reduced their stakes in the company. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Precigen during the 2nd quarter worth approximately $227,000. California State Teachers Retirement System grew its holdings in shares of Precigen by 622.5% in the second quarter. California State Teachers Retirement System now owns 1,236,889 shares of the biotechnology company’s stock valued at $7,050,000 after purchasing an additional 1,065,700 shares in the last quarter. Syon Capital LLC purchased a new position in shares of Precigen in the second quarter valued at $86,000. AXQ Capital LP increased its position in Precigen by 223.7% in the second quarter. AXQ Capital LP now owns 116,978 shares of the biotechnology company’s stock worth $667,000 after purchasing an additional 80,837 shares during the last quarter. Finally, Wellington Management Group LLP increased its position in Precigen by 9.2% in the second quarter. Wellington Management Group LLP now owns 555,230 shares of the biotechnology company’s stock worth $3,165,000 after purchasing an additional 46,796 shares during the last quarter. Institutional investors own 33.51% of the company’s stock.
About Precigen
Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.
The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.
Read More
- Five stocks we like better than Precigen
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for Precigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precigen and related companies with MarketBeat.com's FREE daily email newsletter.
